Literature DB >> 1622625

The biology of breast tumor progression. Acquisition of hormone independence and resistance to cytotoxic drugs.

F Leonessa1, V Boulay, A Wright, E W Thompson, N Brünner, R Clarke.   

Abstract

Many breast tumors appear to follow a predictable clinical pattern, being initially responsive to endocrine therapy and to cytotoxic chemotherapy but ultimately exhibiting a phenotype resistant to both modalities. Using the MCF-7 human breast cancer cell line as an example of an 'early' phenotype (estrogen and progesterone receptor positive, steroid responsive, low metastatic potential), we have isolated and characterized a series of hormone-independent but hormone-responsive variants (MIII and MCF7/LCC1). However, these variants remain responsive to both antiestrogens and cytotoxic drugs (methotrexate and colchicine). MIII and MCF7/LCC1 cells appear to mimic some of the critical aspects of the early progression to a more aggressive phenotype. An examination of the phenotype of these cells suggests that some hormone-independent breast cancer cells are derived from hormone-dependent parental cells. The development of a hormone-independent phenotype can arise independently of acquisition of a cytotoxic drug resistant phenotype.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1622625     DOI: 10.3109/02841869209088890

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  9 in total

1.  Influence of antiestrogens on the migration of breast cancer cells using an in vitro wound model.

Authors:  A C Mathew; T T Rajah; G M Hurt; S M Abbas Abidi; J J Dmytryk; J T Pento
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

2.  Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems.

Authors:  Lilian E van Vlerken; Zhenfeng Duan; Steven R Little; Michael V Seiden; Mansoor M Amiji
Journal:  AAPS J       Date:  2010-02-09       Impact factor: 4.009

Review 3.  Hormone resistance, invasiveness, and metastatic potential in breast cancer.

Authors:  R Clarke; E W Thompson; F Leonessa; J Lippman; M McGarvey; T L Frandsen; N Brünner
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

4.  Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells.

Authors:  Lyndsay V Rhodes; Melyssa R Bratton; Yun Zhu; Syreeta L Tilghman; Shannon E Muir; Virgilio A Salvo; Chandra R Tate; Steven Elliott; Kenneth P Nephew; Bridgette M Collins-Burow; Matthew E Burow
Journal:  Exp Cell Res       Date:  2011-08-30       Impact factor: 3.905

5.  Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk.

Authors:  Lyndsay V Rhodes; James W Antoon; Shannon E Muir; Steven Elliott; Barbara S Beckman; Matthew E Burow
Journal:  Mol Cancer       Date:  2010-11-18       Impact factor: 27.401

Review 6.  Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression.

Authors:  R Clarke; T Skaar; K Baumann; F Leonessa; M James; J Lippman; E W Thompson; C Freter; N Brunner
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

7.  Hormone dependence of breast cancer cells and the effects of tamoxifen and estrogen: 31P NMR studies.

Authors:  J Ruiz-Cabello; K Berghmans; O Kaplan; M E Lippman; R Clarke; J S Cohen
Journal:  Breast Cancer Res Treat       Date:  1995-03       Impact factor: 4.872

8.  Genomic insights into triple-negative and HER2-positive breast cancers using isogenic model systems.

Authors:  Prakriti Mudvari; Kazufumi Ohshiro; Vasudha Nair; Anelia Horvath; Rakesh Kumar
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

9.  MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer.

Authors:  F Leonessa; D Green; T Licht; A Wright; K Wingate-Legette; J Lippman; M M Gottesman; R Clarke
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.